Characterisation of natural killer cells and CD56+ T-cells in sarcoidosis patients

European Respiratory Journal

Volumn 26, Issue 1, 2005, Pages 77-85

  Katchar, K ^a,c   Soderstrom K ^b   Wahlstrom, J ^a   Eklund, A ^a   Grunewald, J ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Bronchoalveolar lavage fluid; CD56+ T cells; Killer inhibitory receptors; Natural killer cells; Sarcoidosis

Indexed keywords

CD56 ANTIGEN; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; HLA E ANTIGEN; LYMPHOCYTE RECEPTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CELL TYPE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LUNG FUNCTION TEST; LUNG LAVAGE; LUNG SARCOIDOSIS; LYMPHOCYTE SUBPOPULATION; MALE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PHENOTYPE; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THORAX RADIOGRAPHY;

ADULT; ANTIGENS, CD56; BRONCHOALVEOLAR LAVAGE FLUID; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FLOW CYTOMETRY; HUMANS; INFLAMMATION MEDIATORS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SARCOIDOSIS, PULMONARY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES;

EID: 21744436966     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.05.00030805     Document Type: Article

References (24)

1. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22: 633-640.
2. Carson WE, Fehniger TA, Caligiuri MA. CD56bright natural killer cell subsets: characterization of distinct functional responses to interleukin-2 and the c-kit ligand. Eur J Immunol 1997; 27: 354-360.
3. Gottschalk LR, Bray RA, Kaizer H, Gebel HM. Two populations of CD56 (Leu-19)+/CD16+ cells in bone marrow transplant recipients. Bone Marrow Transplant 1990; 5: 259-264.
4. Middleton D, Curran M, Maxwell L. Natural killer cells and their receptors. Transpl Immunol 2002; 10: 147-164.
5. Lanier LL, Le AM, Civin CI, Loken MR, Phillips JH. The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes. J Immunol 1986; 136: 4480-4486.
6. Pittet MJ, Speiser DE, Valmori D, Cerottini JC, Romero P. Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression. J Immunol 2000; 164: 1148-1152.
7. Ohkawa T, Seki S, Dobashi H, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001; 103: 281-290.
8. Agostini C, Trentin L, Zambello R, et al. Phenotypical and functional analysis of natural killer cells in sarcoidosis. Clin Immunol Immunopathol 1985; 37: 262-275.
9. Semenzato G, Agostini C, Pezzutto A, et al. Distribution of natural killer cells in sarcoidosis. J Clin Lab Immunol 1984; 13: 25-28.
10. Robinson BW, Pinkston P, Crystal RG. Natural killer cells are present in the normal human lung but are functionally impotent. J Clin Invest 1984; 74: 942-950.
11. Consensus conference: activity of sarcoidosis. Third WASOG meeting, Los Angeles, USA, September 8-11, 1993. Eur Respir J 1994; 7: 624-627.
12. Costabel U. CD4/CD8 ratios in bronchoalveolar lavage fluid: of value for diagnosing sarcoidosis? Eur Respir J 1997; 10: 2699-2700.
13. Eklund A, Blaschke E. Relationship between changed alveolar-capillary permeability and angiotensin converting enzyme activity in serum in sarcoidosis. Thorax 1986; 41: 629-634.
14. Lima M, Teixeira MA, Queiros ML, et al. Immunophenotypic characterization of normal blood CD56+lo versus CD56+hi NK-cell subsets and its impact on the understanding of their tissue distribution and functional properties. Blood Cells Mol Dis 2001; 27: 731-743.
15. Tarazona R, Casado JG, Delarosa O, et al. Selective depletion of CD56(dim) NK cell subsets and maintenance of CD56(bright) NK cells in treatment-naive HIV-1-seropositive individuals. J Clin Immunol 2002; 22: 176-183.
16. Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault JC. Lung volumes and forced ventilatory flows. Report working party standardization of lung function tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J 1993; 6: Suppl. 16, S5-S40.
17. Meyer KC, Soergel P. Variation of bronchoalveolar lymphocyte phenotypes with age in the physiologically normal human lung. Thorax 1999; 54: 697-700.
18. Lanier LL. The origin and functions of natural killer cells. Clin Immunol 2000; 95: S14-S18.
19. Lanier LL. Natural killer cell receptors and MHC class I interactions. Curr Opin Immunol 1997; 9: 126-131.
20. Fu Y, Nathan DM, Li F, Li X, Faustman DL. Defective major histocompatibility complex class I expression on lymphoid cells in autoimmunity. J Clin Invest 1993; 91: 2301-2307.
21. Mizuki M, Eklund A, Grunewald J. Altered expression of natural killer cell inhibitory receptors (KIRs) on T cells in bronchoalveolar lavage fluid and peripheral blood of sarcoidosis patients. Sarcoidosis Vasc Diffuse Lung Dis 2000; 17: 54-59.
22. Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum 2002; 46: 1763-1772.
23. Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 2001; 97: 3146-3151.
24. Norris S, Dohertv DG, Collins C, et al. Natural T cells in the human liver: cytotoxic lymphocytes with dual T cell and natural killer cell phenotype and function are phenotypically heterogenous and include Valpha24-JalphaQ and gammadelta T cell receptor bearing cells. Hum Immunol 1999; 60: 20-31.